Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MLYS - Mineralys Therapeutics Inc


IEX Last Trade
12.44
-0.130   -1.045%

Share volume: 106,900
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$12.57
-0.13
-1.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
6.89%
1 Month
-0.72%
3 Months
-0.08%
6 Months
-15.81%
1 Year
-3.42%
2 Year
-32.70%
Key data
Stock price
$12.44
P/E Ratio 
0.00
DAY RANGE
$12.16 - N/A
EPS 
$0.00
52 WEEK RANGE
$5.85 - $16.91
52 WEEK CHANGE
-$0.04
MARKET CAP 
617.108 M
YIELD 
N/A
SHARES OUTSTANDING 
49.727 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.62
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$191,610
AVERAGE 30 VOLUME 
$209,994
Company detail
CEO:
Region: US
Website:
Employees: 12
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

at mineralys therapeutics we aim to redefine hypertension diagnosis, management and treatment. we are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.

Recent news